Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity

Immune checkpoint inhibition (ICI) has improved outcomes for some patients with advanced malignancies, but relatively few have a complete response. Alcohol use is common and impairs adaptive immunity. Here, we explored the link between alcohol use and ICI efficacy in mouse models of lung and bladder cancers and performed a retrospective assessment of a cohort of patients with cancer receiving ICI therapy. In both mouse models, a regimen of moderate-to-heavy ethanol intake reduced ICI efficacy by ∼50% and increased tumor recurrence. In patients with lung cancer, regular alcohol use was associated with reduced survival benefit from ICI. Effects were less definitive in patients with bladder cancer, melanoma, and head and neck cancer, in whom alcohol use reporting was too limited. In mice bearing MB49 bladder tumors, ethanol intake reduced the number of tumor-infiltrated T cells favoring T helper 17 cell (T H 17 cell) over T H 1 cell phenotypes in tumor-associated CD4 + T cells. It also reduced the number of tissue-resident memory T cells, increased the proportion of T cells expressing the alternative immune checkpoint receptor TIGIT, and induced SREBP-mediated lipid signaling in tumor-associated T cells. Blocking TIGIT with antibodies or, to a lesser extent, inhibiting SREBP signaling with betulin improved the efficacy of PD1 receptor blockade. The findings suggest that regular alcohol use negatively affects ICI efficacy, which may be counteracted by cotargeting TIGIT. Future incorporation of patients’ alcohol use in cancer databases will help define its effect on the outcome of various therapies in multiple cancers.

Authors

Institutions

Publication Details

Journal
Science Signaling
Published
2026-11-17
DOI
https://doi.org/10.1126/scisignal.aef1375
Citations
4
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
8.49

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity

Chad Victor Pecot, Kristen N. Gilley, Benjamin Garrett Vincent, Leon G. Coleman et al.
4 citations
Science Signaling
Cancer Immunotherapy and Biomarkers
8.49
article

Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity

Chad Victor Pecot, Kristen N. Gilley, Benjamin Garrett Vincent, Leon G. Coleman, Mark G. Woodcock, Jason A. Garness, Baylee R. Materia, Ali Younas Khan, Wolfgang A. Beck, Mitra Shabrang, Brandon Carpenter
article en
4 citations

Abstract

Immune checkpoint inhibition (ICI) has improved outcomes for some patients with advanced malignancies, but relatively few have a complete response. Alcohol use is common and impairs adaptive immunity. Here, we explored the link between alcohol use and ICI efficacy in mouse models of lung and bladder cancers and performed a retrospective assessment of a cohort of patients with cancer receiving ICI therapy. In both mouse models, a regimen of moderate-to-heavy ethanol intake reduced ICI efficacy by ∼50% and increased tumor recurrence. In patients with lung cancer, regular alcohol use was associated with reduced survival benefit from ICI. Effects were less definitive in patients with bladder cancer, melanoma, and head and neck cancer, in whom alcohol use reporting was too limited. In mice bearing MB49 bladder tumors, ethanol intake reduced the number of tumor-infiltrated T cells favoring T helper 17 cell (T H 17 cell) over T H 1 cell phenotypes in tumor-associated CD4 + T cells. It also reduced the number of tissue-resident memory T cells, increased the proportion of T cells expressing the alternative immune checkpoint receptor TIGIT, and induced SREBP-mediated lipid signaling in tumor-associated T cells. Blocking TIGIT with antibodies or, to a lesser extent, inhibiting SREBP signaling with betulin improved the efficacy of PD1 receptor blockade. The findings suggest that regular alcohol use negatively affects ICI efficacy, which may be counteracted by cotargeting TIGIT. Future incorporation of patients’ alcohol use in cancer databases will help define its effect on the outcome of various therapies in multiple cancers.

Science SignalingVol. 19(964)
University of North Carolina at Chapel Hill (US), UNC Lineberger Comprehensive Cancer Center (US)
North Carolina Biotechnology Center, Lung Cancer Research Foundation, Free To Breathe, Center for Alcohol Studies, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, National Cancer Institute, School of Medicine, University of North Carolina at Chapel Hill, Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill
Good health and well-being
Openalex Percentile: Top 3%
Cancer Immunotherapy and Biomarkers
8.49
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon